Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 8/20 | 0.44 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850634 | 0.91 | GRM1 (0.44) | TNK2GRM1NAMPTGRM5CDK9 | |
| SCHEMBL4848471 | 0.84 | GRM5 (0.48) | TNK2GRM1GRM5 | |
| SCHEMBL14019009 | 0.84 | GRM5 (0.49) | TNK2GRM1GRM5 | |
| SCHEMBL2297459 | 0.84 | NAMPT (0.58) | TNK2GRM1NAMPTGRM5PDK4 | |
| SCHEMBL4848600 | 0.81 | GRM1 (0.54) | GRM1NAMPTGRM5CDK9PDK4 | |
| SCHEMBL4847387 | 0.75 | GRM1 (0.50) | GRM1NAMPTGRM5CDK9PDK4 | |
| SCHEMBL14695387 | 0.75 | HDAC3 (0.47) | GRM1NAMPTGRM5PDK4KIT | |
| SCHEMBL14695419 | 0.75 | GPR119 (0.46) | GRM1NAMPTGRM5PDK4CDK7 | |
| SCHEMBL7838136 | 0.75 | GRM5 (0.55) | GRM1NAMPTGRM5PDK4JAK1 | |
| SCHEMBL949070 | 0.74 | GRM1 (0.48) | TNK2GRM1NAMPTGRM5CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | TNK2 2378/4885GRM1 627/4885NAMPT 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.